LUCIUS 卢修斯 培米替尼 Pemigatinib胆管癌

培米替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Pemigatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Each LuciPem tablet contains: Pemigaticib 4.5mg

胆管癌

Indication:

LUCiUS

Lucirem is 2 kinase mbicitor indicated for the treatiment
of 3calts w.ln preriousty treated, umresectable locally
advanced er metastatic cholangiocarcizoma with a

PHARMACEUTICALS

fibroblast zromth
factor recentor 2(FGFR2)fsion or other rearran
we)usion or other zearrangement
as detected by an FDA-amrt
Dosage and Use:

LuciPem4.5

ig drally once danly for 14
Cd Dy7 days off therany in 21.
ent until disease progression

Pemigatinib Tablets

Heratic imprirment: she recommended
dosugr of lsciPem 1s 9 mg orally once da l for 14

FDA批准

Conserstre days followed by 7 days off herapy in21-

Rx Only

1abets stoold he swallowcad mhole & not cheved
Storage: in a dry place and store at 20°Cto 25FC

4.5mg

re in reguancy and Lactat:3n

PLEASE SEEPACKAGEINSERT
Manufactured and Marketed
LUCIUS

权威认证

gpAayttany cistrict, Vientiane

Warning To te sold by nend on preseripdion

14 Tablets

口碑质量

适应症:

适用于成纤维细胞生长因子受体2(FGFR2)融合或重排,
且先前接受过治疗、不可切除的晚期或转移性胆管癌的成

人患者。
推荐剂量:

1、每天口服一次,每次13.5mg,连续服用14天,停药7天;
继续治疗,直至疾病进展或出现耐受;
2、整片吞咽,随或不随食物。